

Implications of Axis Inhibition Protein 2 in Breast Cancer Progression

SUNG YONG AHN^{1,2,3} and CHRIS HYUNCHUL JO^{1,2,3}

¹Department of Orthopaedic Surgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea;

²Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;

³Institute of Reproductive Medicine and Population, Medical Research Center at Seoul National University, Seoul, Republic of Korea

Abstract. *Background/Aim:* Although axis inhibition protein 2 (Axin2) has been reported to act as a tumour suppressor, recent findings suggest that it exhibits oncogenic effects by mediating Snail1-induced epithelial-mesenchymal transition (EMT) in breast cancer cells. EMT is a crucial biological process involved in the initiation of metastasis in cancer progression. This study elucidated the biological significance and mechanism of Axin2 in breast cancer using transcriptomic and molecular techniques. *Materials and Methods:* The expression of Axin2 and Snail1 in MDA-MB-231 breast cancer cells was determined by western blotting analysis, and the role of Axin2 in breast cancer tumorigenesis was investigated in xenograft mouse models constructed using pLKO-Tet-shAxin2-transfected triple negative (TN) breast cancer cells. Additionally, the expression levels of EMT markers were determined using qRT-PCR, and clinical data were analysed using Kaplan-Meier (KM) plotter and The Cancer Genome Atlas (TCGA). *Results:* Axin2 knockdown significantly decreased ($p < 0.001$) the proliferation of MDA-MB-231 cells in vitro and attenuated ($p < 0.05$) the tumorigenic potential of the cells in vivo. Moreover, Axin2 knockdown significantly

increased the relative mRNA levels of epithelial markers but decreased the expression of mesenchymal markers in MDA-MB-231 cells. *Conclusion:* Axin2 may be involved in the progression of breast cancer, particularly triple-negative breast cancer, through the regulation of Snail1-induced EMT, making it a potential therapeutic target.

Breast cancer is the most common type of cancer among women (1), and the second leading cause of cancer-related death in women worldwide, with approximately more than one million new cases recorded yearly (2). Triple-negative (TN) breast cancer is a subtype of cancer that does not express the oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). TN breast cancer is characterized by high metastatic potential, invasiveness, relapse tendency, and poor prognosis. TN breast cancer is insensitive to endocrine therapy or HER2 treatment owing to the lack of ER, PR, and HER2 expression (3). Currently available breast cancer treatments remain unsatisfactory, indicating the need for further studies on potential therapeutic targets for effective treatment of the disease.

There are 19 Wnt genes in mammalian genomes, and the canonical Wnt signalling pathway plays a critical role in mammary gland morphogenesis via the regulation of epithelial-mesenchymal cell interactions (4). Moreover, aberrant activation of the Wnt signalling pathway is a common occurrence in breast cancer and is known to play a critical role in breast cancer progression (5, 6). Wnt signalling activation is induced by the binding of a Wnt ligand to its co-receptors, seven-transmembrane-domain Frizzled receptors, and one of the low-density lipoprotein (LDL) receptor-related proteins (LRPs, LRP5/LRP6). Moreover, β -catenin is a major player in the Wnt signalling pathway. Axis inhibition protein 2 (Axin2) is a negative regulator of the canonical Wnt signalling pathway and suppresses signalling activity in the absence of a Wnt ligand. Axin2 forms part of a β -catenin destruction complex

Correspondence to: Sung Yong Ahn (ORCID ID: 0000-0002-6029-1853), Ph.D., Department of Orthopaedic Surgery, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Tel: +82 8702901, e-mail: davidahn@snu.ac.kr; Chris Hyunchul Jo (ORCID ID: 0000-0002-6161-5442), MD, Ph.D., Department of Orthopaedic Surgery, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Tel: +82 8702901, e-mail: chrisjo@snu.ac.kr

Key Words: Axin2, Snail1, EMT, triple negative breast cancer.



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table I. *Primer sequences.*

Target primers	Primer sequences
Axin2	Forward; 5'-AAGGGCCAGGTCACCAAAC-3' Reverse; 5'-CCCCCAACCCATCTTCGT-3'
Snail1 (SNAI1)	Forward; 5'-TCTCTGAGGCCAAGGATCTC-3' Reverse; 5'-CTTCGGATGTGCATCTTGAG-3'
β-Actin (ACTB)	Forward; 5'-ATAGCACAGCCTGGATAGCAACGTAC-3' Reverse; 5'-CACCTTCTACAATGAGCTGCGTGTG-3'
PCNA	Forward; 5'-GGCGTGAACCTCACCAGTAT-3' Reverse; 5'-TTCTCCTGGTTTGGTGCTC-3'
Ki67	Forward; 5'-AAGCCCTCCAGCTCCTAGTC-3' Reverse; 5'-GCAGGTTGCCACTCTTTCTC-3'
Claudin1 (CLDN1)	Forward; 5'-GGCTGCTTTGCTGCAACTGTC-3' Reverse; 5'-GAGCCGTGGCACCTTACACG-3'
Occludin (OCLN)	Forward; 5'-CGGTCTAGGACGCAGCAGAT-3' Reverse; 5'-AAGAGGCCTGGATGACATGG-3'
E-cadherin (CDH1)	Forward; 5'-GGTTTTCTACAGCATCACCG-3' Reverse; 5'-GCTTCCCCATTTGATGACAC-3'
N-cadherin (CDH2)	Forward; 5'-TGAAACGGCGGGATAAAGAG-3' Reverse; 5'-GGCTCCACAGTATCTGGTTG-3'
β-Catenin (CTNNB1)	Forward; 5'-ATTGATTTCGAAACCTTGCCC-3' Reverse; 5'-AGCTCCAGTACACCTTCTA-3'

with adenomatous polyposis coli (APC), glycogen synthase kinase 3 beta (GSK3β), and casein kinase 1 (CK1), which contributes to the regulation of β-catenin degradation (7). This destruction complex suppresses the expression of downstream β-catenin target genes that modulate various cellular functions, such as apoptosis, differentiation, proliferation, migration, and tumorigenesis. Therefore, *Axin2* was initially categorized as a potential tumour suppressor gene.

However, the activation of the Wnt signalling pathway induces Dishevelled (Dsh) phosphorylation, facilitating the subsequent translocation of Axin proteins by activated Dsh to the membrane to bind to the LRP5 receptor (8, 9). This sequence of activities following the activation of the Wnt signalling pathway leads to the inactivation of the β-catenin destruction complex. β-catenin is therefore released from the degradation machinery and accumulates in the cytoplasm where it is further translocated to the nucleus. In the nucleus, β-catenin is involved in the transcription of Wnt target genes *via* interaction with the transcription factors T-cell factor/lymphoid enhancer-binding factor (Tcf/Lef) (9).

As one of the Wnt target genes, *Axin2* is frequently over-expressed in various cancers, including hepatoblastoma and colorectal, lung, cervical, and breast cancers, owing to aberrant activation of the Wnt signalling pathway (10-12). Specifically, *Axin2* over-expression markedly increases the activity of *Snail1* in cancer cells owing to increased nuclear export of GSK3β, a dominant kinase that modulates the stability of *Snail1*. The increase in *Snail1* activity down-regulates the expression of E-cadherin, a key transmembrane

cell adhesion protein, by binding to E-boxes in the E-cadherin promoter, leading to epithelial-mesenchymal transition (EMT), which is the first step in cancer cell invasion and metastasis (10). These findings suggest that *Axin2* serves as an oncogene rather than a tumour suppressor through its mediation of Snail1-induced EMT (10, 13). Additionally, some findings have shown that Axin proteins are involved in various non-canonical signalling pathways, including the Ras/ERK and SAPK/JNK pathways (14-16).

Overall, it could be speculated that *Axin2* may be a multifunctional protein involved in several aspects of the molecular mechanisms underlying cancer. Here, we elucidated the mechanism of *Axin2* in breast cancer, using human breast cancer cells and xenograft mouse models.

Materials and Methods

Cell culture and establishment of Axin2 knock-down MDA-MB-231 cells. A human TN breast cancer cell line, MDA-MB-231 (17), and 293T cells were purchased from the Korean Cell Line Bank (Seoul, Republic of Korea), and the cells were maintained in 10% foetal bovine serum (FBS; Invitrogen, Waltham, MA, USA) containing Roswell Park Memorial Institute (RPMI) 1640 (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) and Dulbecco's Modified Eagle's medium (DMEM; Gibco BRL, Grand Island, NY, USA), respectively. The pLKO-Tet-On vector (Addgene, Cambridge, MA, USA) was used to express short hairpin RNA (shRNA) targeted against *Axin2* (pLKO-Tet-*shAxin2*). *Axin2* oligos were inserted into the AgeI/EcoRI restriction sites of the vector to generate inducible shRNA targeted against *Axin2*. The *Axin2* oligo sequence was as follows: 5'-ACCACCACTACATCCACCA-3'.




Figure 1. *Axin2* knockdown suppressed *Snail1* expression in MDA-MB-231 cells. (A) The protein expression of *Axin2* and *Snail1* in MDA-MB-231 cells transfected with pLKO-Tet-shAxin2 in the presence or absence of doxycycline (Dox) treatment was determined by western blotting. (B) The mRNA expression of *Axin2* and *Snail1* in MDA-MB-231 cells transfected with pLKO-Tet-shAxin2 in the presence or absence of Dox treatment was determined using qRT-PCR. Significant differences between groups were determined using the two-tailed Student's *t*-test [****** $p < 0.01$ and ******* $p < 0.001$ compared with Dox (-)]. All experiments were conducted in triplicate.

To generate lentiviruses, 293T cells were co-transfected with 1.8 μg of *Axin2* shRNA-encoding plasmid, 0.6 μg of pMD2.G (Addgene), and 1.2 μg of psPAX2 (Addgene) plasmids using Lipofectamine 2000 (Invitrogen). Lentiviral supernatant was collected every 24 h for 3 days and used to infect MDA-MB-231 cells at a multiplicity of infection (MOI) of one. Transduced cells were then selected using a medium containing 1 $\mu\text{g}/\text{ml}$ of puromycin (Sigma-Aldrich, St. Louis, MO, USA). MDA-MB-231 cells stably expressing *Axin2* shRNA were grown in RPMI1640 supplemented with 10% Tet-approved FBS (HyClone Laboratories, Inc., Logan, UT, USA) and 1 $\mu\text{g}/\text{ml}$ of puromycin. *Axin2* shRNA expression was induced by culturing cells in the presence of 5 $\mu\text{g}/\text{ml}$ of doxycycline (Dox; Sigma-Aldrich).

Cell proliferation assay. A cell proliferation assay was performed to determine whether *Axin2* expression affected the viability of MDA-MB-231 cells. The assay was performed at three time points of 24, 48, and 72 h. Briefly, MDA-MB-231 cells were plated in 96-well plates at a density of 5×10^3 cells per well (Thermo Fisher, Waltham, MA, USA), followed by the addition of Cell Counting Kit-8 (CCK-8) solution (Dojindo, Kumamoto, Japan) diluted with serum-free RPMI-1640 at a ratio of 1:10. The plates were incubated in the dark at 37°C for 1 h under a 5% CO_2 atmosphere, and absorbance was

measured at 450 nm using a microplate reader with SoftMax® Pro Software (Molecular Devices, San Jose, CA, USA).

Tumour growth in mice. Six female 6-week-old BALB/c-nu/nu mice (BALB/c Slc-nu/nu; Japan SLC, Inc., Hamamatsu, Japan) were randomized into two groups ($n=3$ per group). A total of 5×10^5 of pLKO-Tet-shAxin2-transfected MDA-MB-231 cells were suspended in 100 μl of phosphate-buffered saline (PBS) and subcutaneously injected into both sides of the mammary fat pad. For the experimental group, the cells were pre-treated with 5 $\mu\text{g}/\text{ml}$ of Dox for 48 h before injection. After cell injection, mice in the experimental group were administered Dox at 10 mg/kg body weight (MPK) by intraperitoneal injection for five consecutive days per week for 21 days. Mice in the control group were administered PBS according to the same schedule as those in the experimental group. Tumour volume was determined every 3 days by measuring the length and width of the tumour nodules (18) and calculated using the following formula: $V=(L \times W^2)/2$ (L, length; W, width). At the end of the study period, the mice were sacrificed, and the tumour nodules removed. Tissue lysate was isolated from tumour cryosections using Pro-prep protein extraction solution (Intron, Republic of Korea), and the expression of *Axin2* and *Snail1* proteins was quantified using western blot analysis.




Figure 2. *Axin2* knockdown suppressed the proliferation of MDA-MB-231 cells. (A) The viability of doxycycline (Dox)-treated cells was significantly lower than that of untreated MDA-MB-231 cells at the indicated time points. (B) The mRNA expression levels of *Ki67* and *PCNA* in Dox-treated cells were significantly lower than those of the untreated cells. The results were analysed using the two-tailed Student's *t*-test [*** $p < 0.001$ compared with Dox (-)]. All experiments were conducted in triplicate.

Western blotting. Western blot analysis was performed for Dox-treated or untreated pLKO-Tet-*shAxin2*-transfected MDA-MB-231 cells and tumour nodules obtained from the animal study. Total protein extraction was performed using lysis buffer (RIPA buffer; Cell Signaling Technology, Inc., Danvers, MA, USA) and then the protein was resolved on a 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Thereafter, the proteins were transferred to polyvinylidene difluoride (PVDF) membranes (EMD Millipore, Billerica, MA, USA), blocked using 5% non-fat milk, and then incubated with antibodies against *Axin2* (working dilution 1/1,000; Abcam), *Snail1* (working dilution 1/1,000, Cell Signaling Technology), or tubulin (working dilution 1/5,000; Cell Signaling Technology) at 25°C for 2 h. Antibody reaction was detected using an enhanced chemiluminescence (ECL) detection system (Pierce Biotechnology, Rockford, IL, USA).

Quantitative RT-PCR (qRT-PCR). Total RNA was extracted from MDA-MB-231 cells using TRIzol™ reagent (Invitrogen, Waltham, MA, USA), and cDNA was synthesized using AccuPower RT PreMix (Bioneer, Daejeon, Republic of Korea) according to the manufacturer's protocol. qRT-PCR was performed using the StepOnePlus system with TB Green Premix Ex Taq II (Takara, Tokyo, Japan) and specific primers (Table I). The relative expression of the genes was normalized to that of β -actin (*ACTB*; internal control) and calculated using the $2^{-\Delta\Delta CT}$ method (19).

Bioinformatic analysis. The effect of *Axin2* expression in patients with breast cancer was analysed using Kaplan-Meier (KM) Plotter and the Human Genome Atlas for cancer genomics. Information on TN breast cancer was obtained from The Cancer Genome Atlas (TCGA). Data of *Axin2* mRNA expression and *SNAIL1* protein




Figure 3. *Axin2* knockdown attenuated the tumorigenic potential of MDA-MB-231 cells in vivo. (A) The tumorigenic ability of doxycycline (Dox)-treated MDA-MB-231 cells was significantly attenuated compared with the untreated cells. (B) Tumour weight was markedly reduced in the Dox-treated group compared with the untreated group. (C) Body weight. (D) There was a decrease in *Axin2* and *Snail1* expression levels in tumour nodules obtained from mice injected with Dox-treated MDA-MB-231 cells. Tumour tissues were collected and the protein expression of *Axin2* and *Snail1* in the tumour lysates was determined using western blot analysis. (E) *Axin2* and *Snail1* protein abundances from tumour lysates. The band intensity on each blot was normalized to the loading control and the relative protein abundance is shown as a ratio to that of the untreated control. The results were analysed using the two-tailed Student's *t*-test [$*p<0.05$, $**p<0.01$, and $***p<0.001$ compared with Dox (-)]. All experiments were conducted in triplicate.




Figure 4. Axin2 knockdown alleviated Snail1-mediated EMT in MDA-MB-231 cells. (A) The mRNA expression levels of Claudin1, Occludin, and E-cadherin were markedly higher in Dox-treated cells than in untreated cells. (B) The mRNA expression of N-cadherin and β -catenin was markedly lower in Dox-treated cells than in untreated MDA-MB-231 cells. (C) The mRNA expression of Snail1 was significantly lower in Axin2-knockdown cells than in untreated cells. The results were analysed using the two-tailed Student's t-test [** $p < 0.01$ and *** $p < 0.001$ compared with Dox (-)]. All experiments were conducted in triplicate.




Figure 5. Breast cancer patients with high *Axin2* and *Snai1* expression showed poor prognosis. *In silico* data from patients with breast cancer correlated with *Axin2* expression. (A) Kaplan-Meier analysis of overall survival (OS) ($n=126$, $p=0.1692$) curve for patients with triple negative (TN) breast cancer. The *Axin2* probe was selected and used for survival analysis. (B) Kaplan-Meier analysis of OS ($n=95$, $p=0.0273$) curve for patients with triple negative (TN) breast cancer following TCGA. The *Snai1* (*SNAI1*) probe was selected and used for survival analysis.

expression in breast tissues were selected. KM plotter was used to analyse the survival rate of patients with TN breast cancer depending on *Axin2* expression.

Statistical analysis. All statistical analyses were performed using the SPSS 26 statistical package (SPSS, Inc., Chicago, IL, USA), and data were expressed as the mean±standard deviation (SD) of values from at least three independent experiments. Statistical significance was determined using two-tailed Student's *t*-tests. Data were expressed as the mean±standard error of mean (SEM) for tumour volume. The difference between groups' volume of tumour nodules was assessed using the Mann-Whitney *U*-test. Mean values were considered statistically significant at $p<0.05$.

Ethics approval and consent to participate. All animal experiments were approved by the Seoul Metropolitan Government Seoul National University Boramae Medical Center Institutional Animal Care and Use Committee (IACUC No. 2022-0002).

Results

***Axin2* knockdown inhibited *Axin2* and *Snai1* expression in MDA-MB-231 cells.** The effect of *Axin2* knockdown on *Axin2* and *Snai1* expression was examined at the protein and mRNA levels, using western blot analysis and qRT-PCR, respectively. *Axin2* knockdown followed by Dox treatment significantly decreased the protein expression of *Axin2* and *Snai1* in MDA-MB-231 cells (Figure 1A). Similarly, qRT-

PCR showed that Dox treatment significantly decreased the mRNA levels of *Snai1* ($p<0.001$) and *Axin2* ($p<0.01$) compared with those of the untreated group (Figure 1B). Overall, these results suggest that *Snai1* expression in breast cancer cells is regulated by *Axin2*.

***Axin2* knockdown suppressed the proliferation of MDA-MB-231 cells.** The effect of *Axin2* knockdown on the proliferation of MDA-MB-231 cells was examined. *Axin2* knockdown followed by Dox treatment significantly decreased ($p<0.001$) the proliferation of MDA-MB-231 cells after 24-72 h compared with the untreated group (Figure 2A). Moreover, the Dox-treated group showed significantly lower ($p<0.001$) mRNA levels of *Ki67* and *PCNA* compared with the untreated group (Figure 2B). Overall, these results indicate that *Axin2* exhibits a tumorigenic potential in MDA-MB-231 cells *in vitro*.

***Axin2* knockdown attenuated the tumorigenic potential of MDA-MB-231 cells *in vivo*.** Furthermore, the effect of *Axin2* knockdown on tumorigenesis was examined using tumour xenograft models. *Axin2* knockdown significantly attenuated tumour growth *in vivo* ($p<0.05$) and decreased the relative tumour weight ($p<0.001$; Figure 3A and B) but did not affect the body weight of the mice (Figure 3C). The expression of

Axin2 and *Snail1* in tumour samples was evaluated by western blot analysis. Consistent with the *in vitro* results, there was a significant decrease in *Axin2* ($p < 0.05$) and *Snail1* ($p < 0.01$) expression in Dox-treated tumour nodules (Figure 3D and E). These results indicate that *Axin2* exhibits *Snail1*-mediated tumorigenic potential in MDA-MB-231 cells *in vivo*.

Axin2 knockdown inhibited *Snail1*-induced EMT in MDA-MB-231 cells. The EMT is important for tumorigenesis because the EMT program enhances metastasis, chemical resistance, and tumour stemness. A hallmark of the EMT is the cadherin switch of E-cadherin down-regulation to N-cadherin up-regulation (20). Therefore, the effect of *Axin2* knockdown on the mRNA levels of EMT markers in MDA-MB-231 cells was examined. *Axin2* knockdown significantly increased the mRNA levels of epithelial markers, including Claudin1 (*CLDN1*; $p < 0.01$), Occludin (*OCLN*; $p < 0.01$), and E-cadherin (*CDH1*; $p < 0.01$), but decreased the mRNA levels of the mesenchymal markers N-cadherin (*CDH2*; $p < 0.001$) and β -catenin (*CTNNB1*; $p < 0.001$) compared with the untreated group (Figure 4A and B). Additionally, there was a significant decrease ($p < 0.001$) in the mRNA level of the EMT-promoting transcription factor *Snail1* (*SNAIL1*) in Dox-treated MDA-MB-231 cells (Figure 4C). Overall, these results indicate that *Axin2* acts as an inducer of *Snail1*-mediated EMT in MDA-MB-231 cells.

Breast cancer patients with high Axin2 and Snail1 expression showed poor prognosis. To investigate the effects of *Axin2* expression on the prognosis of patients with TN breast cancer, KM Plotter was used to generate the survival curve of patients with high or low *Axin2* expression. Data of patients with TN breast cancer ($n=126$, *Axin2*; $n=95$, *SNAIL1*) were obtained from the TCGA. TN breast cancer patients with high expression levels of *Axin2* and *Snail1* (*SNAIL1*) showed poor prognosis compared to those with low *Axin2* and *Snail1* (*SNAIL1*) expression levels (Figure 5A and B). Overall, these results indicate that *Axin2* and *Snail1* over-expression is related to poor prognosis in patients with TN breast cancer.

Discussion

The role of *Axin2* in cancer progression is controversial. Even though *Axin2* has been reported to act as a tumour suppressor (21), recent findings suggest that it exerts oncogenic effects in various cancers, including breast cancer. However, most studies on the role of *Axin2* in breast cancer are mainly *in vitro* (10, 22, 23). The *in vitro* effects of genes can sometimes be masked by microenvironmental effects on the tissues. In the present study, the role and biological significance of *Axin2* in breast cancer was elucidated through several experiments using cancer cells and xenograft models.

In the present study, it was observed that high *Axin2* expression may play a crucial role in breast cancer progression. Previous *in vitro* studies have shown that *Axin2* silencing can suppress oncogenic activity by reducing the viability and invasive capability of cancer cells (22, 24). Similarly, *Axin2* expression was significantly related to breast cancer cell proliferation, migration, and invasion in the present study. Moreover, *Axin2* over-expression has been reported to increase the expression of *Snail1*, a well-known zinc-finger transcription factor, by regulating the nuclear export function of GSK3 in breast cancer cell lines (10). Previous studies have shown that *Snail1* directly binds to the E-box sequences located in the *E-cadherin* (epithelial marker) promoter region and suppresses its transcription (25). *Snail1* is regarded as a potent inducer of the EMT in both normal and neoplastic cells. Several studies have shown that *Snail1* is over-expressed in various human malignancies, including bladder (26), cervical (27), colorectal (28), and breast (29) cancers. In breast cancer, *Snail1* expression is related to cancer cell invasion, metastasis, poor prognosis, and recurrence (29, 30). Previous studies have shown that the cellular localization and stability of *Snail1* are related to its phosphorylation status. Generally, *Snail1* is localized in the nucleus of cells, but *Snail1* phosphorylation leads to its translocation from the nucleus to the cytoplasm, where inactivation and subsequent proteasomal degradation occurs (31, 32). Therefore, down-regulation of *Snail1* target genes occurs only in cell lines with pure cytoplasmic expression of *Snail1* (32).

Considering that the prognosis of breast cancer patients is largely dependent on the subtype of breast cancer, there is a need to assess *Axin2* protein expression according to the breast cancer subtype. TN breast cancer is a subtype of breast cancer that is insensitive to endocrine therapy or *HER2* treatment owing to the lack of ER, PR, and *HER2* expression (3, 33). Moreover, TN breast cancer is characterized by high metastatic potential, invasiveness, relapse tendency, and poor prognosis, and therefore necessitates further studies.

The regulatory effect of *Axin2* on *Snail1*-mediated EMT may be a crucial mechanism in the pathogenesis of TN breast cancer. Aberrant activation of the Wnt signalling pathway frequently occurs in TN breast cancer cell lines, and inhibition of the Wnt signalling pathway can induce apoptosis and inhibit cell proliferation and migration in TN breast cancer cell lines (34). In the present study, knockdown of *Axin2* in the MDA-MB-231 TN breast cancer cells attenuated the tumorigenic potential of these cells *in vivo*.

TN breast cancer has the worst prognosis among all breast cancer subtypes because there are few treatment modalities for affected patients (35-37). TN breast cancer is unique in its molecular basis and treatment response (38, 39). Accordingly, the identification of potential therapeutic molecular targets for TN breast cancer may enable the

selection of appropriate treatment modalities to improve the outcome of patients. *Axin2* may serve as an oncogene in breast cancer by mediating *Snail1*-induced EMT. Overall, the results of the present study suggest that *Axin2* may have implications in the pathogenesis of breast cancer and could be a therapeutic target for TN breast cancer treatment.

Conflicts of Interest

All the Authors declare no conflicts of interest in relation to this study.

Authors' Contributions

Conceptualization: Ahn SY; Data curation: Ahn SY; Funding acquisition: Jo CH; Investigation: Ahn SY; Methodology: Ahn SY; Supervision: Jo CH; Writing – original draft: Ahn SY; Writing – review & editing: Ahn SY, Jo CH.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT) of Korea government (2022R1A2C2092854 to C. H. J.).

References

- Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. *CA Cancer J Clin* 63(1): 11-30, 2013. PMID: 23335087. DOI: 10.3322/caac.21166
- Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. *CA Cancer J Clin* 61(2): 69-90, 2011. PMID: 21296855. DOI: 10.3322/caac.20107
- Yin L, Duan JJ, Bian XW and Yu SC: Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res* 22(1): 61, 2020. PMID: 32517735. DOI: 10.1186/s13058-020-01296-5
- Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, Wysolmerski JJ and Millar SE: Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. *Development* 131(19): 4819-4829, 2004. PMID: 15342465. DOI: 10.1242/dev.01347
- Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, Tan LK, Rosen JM and Varmus HE: Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. *Proc Natl Acad Sci U.S.A.* 100(26): 15853-15858, 2003. PMID: 14668450. DOI: 10.1073/pnas.2136825100
- Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP and Brisken C: Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. *Proc Natl Acad Sci U.S.A.* 103(10): 3799-3804, 2006. PMID: 16501043. DOI: 10.1073/pnas.0600065103
- Taketo MM: Shutting down Wnt signal-activated cancer. *Nat Genet* 36(4): 320-322, 2004. PMID: 15054482. DOI: 10.1038/ng0404-320
- Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L and Wu D: Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. *Mol Cell* 7(4): 801-809, 2001. PMID: 11336703. DOI: 10.1016/s1097-2765(01)00224-6
- Cadigan KM and Liu YI: Wnt signaling: complexity at the surface. *J Cell Sci* 119(Pt 3): 395-402, 2006. PMID: 16443747. DOI: 10.1242/jcs.02826
- Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, Fearon ER and Weiss SJ: A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. *Nat Cell Biol* 8(12): 1398-1406, 2006. PMID: 17072303. DOI: 10.1038/ncb1508
- Hughes TA and Brady HJ: Regulation of axin2 expression at the levels of transcription, translation and protein stability in lung and colon cancer. *Cancer Lett* 233(2): 338-347, 2006. PMID: 15885887. DOI: 10.1016/j.canlet.2005.03.026
- Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W and Behrens J: Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. *Mol Cell Biol* 22(4): 1184-1193, 2002. PMID: 11809809. DOI: 10.1128/MCB.22.4.1184-1193.2002
- Wu ZQ, Brabletz T, Fearon E, Willis AL, Hu CY, Li XY and Weiss SJ: Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. *Proc Natl Acad Sci U.S.A.* 109(28): 11312-11317, 2012. PMID: 22745173. DOI: 10.1073/pnas.1203015109
- Jeon SH, Yoon JY, Park YN, Jeong WJ, Kim S, Jho EH, Surh YJ and Choi KY: Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin. *J Biol Chem* 282(19): 14482-14492, 2007. PMID: 17374607. DOI: 10.1074/jbc.M611129200
- Kim SE, Yoon JY, Jeong WJ, Jeon SH, Park Y, Yoon JB, Park YN, Kim H and Choi KY: H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation. *J Cell Sci* 122(Pt 6): 842-848, 2009. PMID: 19240121. DOI: 10.1242/jcs.040493
- Zhang Y, Neo SY, Wang X, Han J and Lin SC: Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. *J Biol Chem* 274(49): 35247-35254, 1999. PMID: 10575011. DOI: 10.1074/jbc.274.49.35247
- Hero T, Bühler H, Kouam PN, Priesch-Grzeszowiak B, Lateit T and Adamietz IA: The triple-negative breast cancer cell line MDA-MB 231 is specifically inhibited by the ionophore salinomycin. *Anticancer Res* 39(6): 2821-2827, 2019. PMID: 31177119. DOI: 10.21873/anticancer.13410
- Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K and Petzelbauer P: Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. *J Invest Dermatol* 120(3): 476-482, 2003. PMID: 12603862. DOI: 10.1046/j.1523-1747.2003.12057.x
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25(4): 402-408, 2001. PMID: 11846609. DOI: 10.1006/meth.2001.1262
- Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and N-cadherin

- switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. *Cells* 8(10): 1118, 2019. PMID: 31547193. DOI: 10.3390/cells8101118
- 21 Salahshor S and Woodgett JR: The links between axin and carcinogenesis. *J Clin Pathol* 58(3): 225-236, 2005. PMID: 15735151. DOI: 10.1136/jcp.2003.009506
- 22 Kim JS, Park SY, Lee SA, Park MG, Yu SK, Lee MH, Park MR, Kim SG, Oh JS, Lee SY, Kim CS, Kim HJ, Chun HS, Kim JS, Moon SM and Kim DK: MicroRNA-205 suppresses the oral carcinoma oncogenic activity *via* down-regulation of Axin-2 in KB human oral cancer cell. *Mol Cell Biochem* 387(1-2): 71-79, 2014. PMID: 24166197. DOI: 10.1007/s11010-013-1872-7
- 23 Ying Y and Tao Q: Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. *Epigenetics* 4(5): 307-312, 2009. PMID: 19633433.
- 24 Kim NH, Cha YH, Kang SE, Lee Y, Lee I, Cha SY, Ryu JK, Na JM, Park C, Yoon HG, Park GJ, Yook JI and Kim HS: p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. *Cell Cycle* 12(10): 1578-1587, 2013. PMID: 23624843. DOI: 10.4161/cc.24739
- 25 van Roy F and Berx G: The cell-cell adhesion molecule E-cadherin. *Cell Mol Life Sci* 65(23): 3756-3788, 2008. PMID: 18726070. DOI: 10.1007/s00018-008-8281-1
- 26 Yu Q, Zhang K, Wang X, Liu X and Zhang Z: Expression of transcription factors snail, slug, and twist in human bladder carcinoma. *J Exp Clin Cancer Res* 29(1): 119, 2010. PMID: 20809941. DOI: 10.1186/1756-9966-29-119
- 27 Chen Z, Li S, Huang K, Zhang Q, Wang J, Li X, Hu T, Wang S, Yang R, Jia Y, Sun H, Tang F, Zhou H, Shen J, Ma D and Wang S: The nuclear protein expression levels of SNAIL and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer *via* the epithelial-mesenchymal transition pathway. *Hum Pathol* 44(10): 2097-2105, 2013. PMID: 23791009. DOI: 10.1016/j.humpath.2013.04.001
- 28 Roy HK, Smyrk TC, Koetsier J, Victor TA and Wali RK: The transcriptional repressor SNAIL is overexpressed in human colon cancer. *Dig Dis Sci* 50(1): 42-46, 2005. PMID: 15712635. DOI: 10.1007/s10620-005-1275-z
- 29 Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R and Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. *Cancer* 103(8): 1631-1643, 2005. PMID: 15742334. DOI: 10.1002/cncr.20946
- 30 Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD and Chodosh LA: The transcriptional repressor Snail promotes mammary tumor recurrence. *Cancer Cell* 8(3): 197-209, 2005. PMID: 16169465. DOI: 10.1016/j.ccr.2005.07.009
- 31 Francí C, Gallén M, Alameda F, Baró T, Iglesias M, Virtanen I and García de Herreros A: Snail1 protein in the stroma as a new putative prognosis marker for colon tumours. *PLoS One* 4(5): e5595, 2009. PMID: 19440385. DOI: 10.1371/journal.pone.0005595
- 32 Domínguez D, Montserrat-Sentís B, Virgós-Soler A, Guaita S, Grueso J, Porta M, Puig I, Baulida J, Francí C and García de Herreros A: Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor. *Mol Cell Biol* 23(14): 5078-5089, 2003. PMID: 12832491. DOI: 10.1128/MCB.23.14.5078-5089.2003
- 33 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology and College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* 31(31): 3997-4013, 2013. PMID: 24101045. DOI: 10.1200/JCO.2013.50.9984
- 34 Bilir B, Kucuk O and Moreno CS: Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. *J Transl Med* 11: 280, 2013. PMID: 24188694. DOI: 10.1186/1479-5876-11-280
- 35 Schnitt SJ: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. *Mod Pathol* 23(Suppl 2): S60-S64, 2010. PMID: 20436504. DOI: 10.1038/modpathol.2010.33
- 36 Allred DC, Brown P and Medina D: The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. *Breast Cancer Res* 6(6): 240-245, 2004. PMID: 15535853. DOI: 10.1186/bcr938
- 37 Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 98(19): 10869-10874, 2001. PMID: 11553815. DOI: 10.1073/pnas.191367098
- 38 Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res* 12(5): R68, 2010. PMID: 20813035. DOI: 10.1186/bcr2635
- 39 Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. *Mol Oncol* 5(1): 5-23, 2011. PMID: 21147047. DOI: 10.1016/j.molonc.2010.11.003

Received November 27, 2022

Revised December 22, 2022

Accepted December 23, 2022